Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day


- Alnylam Community Gives Back in the Communities it Serves at Ten Local Non-Profit Organizations -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.

This Smart News Release features multimedia. View the full release here:

Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual

Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day (Photo: Business Wire)

"One of Alnylam's Core Values is our ‘Commitment to People' both inside and outside the walls of our company," said John Maraganore, Ph.D., Chief Executive Officer at Alnylam. "Our ‘Helping Hands' Community Service Day is a time in which our employee community can pause and focus on giving back to the communities that we serve and to the causes our employees personally connect with. We are thankful to the ten non-profits who have allowed us to share in their missions."

As part of its "Commitment to People" and leadership in local communities, the Company has set aside dedicated time to its second annual company-wide "Helping Hands" Community Service Day. Last year, 280 Alnylam employees participated across six sites around Greater Boston, Cambridge, and the United Kingdom. This year, Alnylam had an even larger impact, with over 400 employees participating and dedicating 2,000 hours to give back to the community. Additionally, this year's effort expanded Alnylam's geographic footprint to include a number of new non-profits in the Cambridge and Greater Boston area, including in Norton, Mass., the site of the Company's future manufacturing facility.

About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across its 3 STArs. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam's pipeline of investigational RNAi therapeutics, please visit

Alnylam Pharmaceuticals, Inc.
Investors and Media
Christine Regan Lindenboom, 617-682-4340
Josh Brodsky, 617-551-8276

Source: Alnylam Pharmaceuticals

News Provided by Acquire Media